Subclinical left ventricular systolic dysfunction in patients with naive acromegaly — assessment with two-dimensional speckle-tracking echocardiography: retrospective study by Popielarz-Grygalewicz, Agata et al.
  
ONLINE FIRST
This is a provisional PDF only. Copyedited and fully formatted version will be made available soon.
ISSN: 0423-104X
e-ISSN: 2299-8306
Subclinical left ventricular systolic dysfunction in patients with
naive acromegaly – assessment with two-dimensional speckle-
tracking echocardiography: retrospective study
Authors:  Agata Popielarz-Grygalewicz, Maria Stelmachowska-Banaś, Jakub
Sławomir Gąsior, Paweł Grygalewicz, Magdalena Czubalska, Wojciech Zgliczyński,
Marek Dąbrowski, Wacław Kochman
DOI: 10.5603/EP.a2020.0021
Article type: Original Paper
Submitted: 2019-12-09
Accepted: 2020-03-20
Published online: 2020-04-15
This article has been peer reviewed and published immediately upon acceptance.
It is an open access article, which means that it can be downloaded, printed, and distributed freely,
provided the work is properly cited.
Articles in "Endokrynologia Polska" are listed in PubMed.
The final version may contain major or minor changes. 
Powered by TCPDF (www.tcpdf.org)
 Subclinical left ventricular systolic dysfunction in patients with naive acromegaly — 
assessment with two-dimensional speckle-tracking echocardiography: retrospective 
study 
Short running title: Systolic dysfunction in acromegaly 
 
10.5603/EP.a2020.0021 
 
 
Agata Popielarz-Grygalewicz1, Maria Stelmachowska-Banaś2, Jakub S. Gąsior3, 1, Paweł 
Grygalewicz4, Magdalena Czubalska1, Wojciech Zgliczyński2, Marek Dąbrowski1, Wacław 
Kochman1 
 
1Clinical Department of Cardiology of National Institute of Cardiology, Bielanski Hospital, 
Warsaw, Poland 
2Department of Endocrinology of the Centre of Postgraduate Medical Education, Warsaw, 
Poland  
3Faculty of Health Sciences and Physical Education, Kazimierz Pulaski University of 
Technology and Humanities, Radom, Poland  
4Independent Public Healthcare Centres (Bemowo-Wlochy), Warsaw, Poland 
 
Corresponding author: Maria Stelmachowska-Banaś, Department of Endocrinology of the 
Centre of Postgraduate Medical Education, Warsaw, Poland, tel: (+48) 22 569 05 29, fax: 
(+48) 22 569 05 29; e-mail: mstelmachowska@cmkp.edu.pl 
 
Abstract 
Introduction: The aim of the study was to evaluate global longitudinal strain (GLS) in 
patients with naive acromegaly with normal left ventricular (LV) ejection fraction (EF). 
Material and methods: Forty-three consecutive patients with naive acromegaly with normal 
LV systolic function as measured by EF, examined from 2008 to 2016, and 52 patients of a 
 control group matched for age and sex underwent two-dimensional speckle-tracking 
echocardiography to assess GLS. 
Results: The median GLS was significantly lower in the acromegaly group than in the control 
group (in %, –16.6 vs. –20.7; p < 0.01). The majority of acromegalic patients (n = 26; 60.5%) 
had abnormal GLS. Patients with impairment in GLS had a longer median duration of 
acromegaly symptoms (in years, 10.0 vs. 5.0; p < 0.05) and greater LV thickness (posterior 
wall in mm, 12.5 vs. 12.0; p < 0.05) compared to those with normal GLS. Patients with 
abnormal GLS had higher IGF-1 concentration, but without statistical significance. Diabetes 
mellitus and arterial hypertension, which are more common in acromegaly, were not 
significant determinants of abnormal GLS. The mean left ventricular mass index (LVMI) was 
increased in the acromegaly group compared to controls (in g/m2, 136 vs. 97; p < 0.01). There 
was a significant negative correlation between LVMI and GLS (R = –0.47; p < 0.01). 
Conclusions: Naive acromegalic patients presented abnormal GLS, which indicates 
subclinical systolic dysfunction in these patients. It has not been proven that arterial 
hypertension and diabetes mellitus are significant determinants of abnormal GLS.  
Key words: acromegaly; global longitudinal strain; left ventricular systolic dysfunction; 
speckle tracking echocardiography; left ventricular ejection fraction; insulin growth factor-1; 
growth hormone 
 
Introduction 
Acromegaly is a rare endocrine disease characterised by increased growth hormone (GH) and 
insulin-like growth factor 1 (IGF-1) levels. It is usually caused by GH-secreting pituitary 
adenoma and rarely by neuroendocrine tumours producing growth hormone-releasing 
hormones [1–2]. 
Acromegaly is a systemic disease that affects different organs, including the cardiovascular 
system, and leads to many comorbidities [3]. 
The main marker in the assessment of heart involvement in the course of various diseases is 
systolic function as measured by ejection fraction (EF). This parameter, evaluated by end-
diastolic and end-systolic volumes according to the biplane Simpson method, remains a 
crucial determinant of the risk stratification of heart failure patients, according to current 
guidelines [4]. 
However, the left ventricular ejection fraction (LVEF) may not truly represent left ventricular 
(LV) systolic function in specific cardiac syndromes, such as asymptomatic severe valve 
diseases, as well as in many other systemic, metabolic, and endocrine disorders [5–7]. 
 Two-dimensional speckle-tracking echocardiography (2D-STE) is a new technique that 
allows the evaluation of longitudinal, radial, and circumferential deformation and offers a 
more sensitive assessment of myocardial contractility [5]. It is based on the tracking of 
characteristic speckle patterns that are created by the interference of ultrasound beams in all 
segments of myocardium [8, 9]. The strain is the percentage change in the myocardial fibre 
length between end-diastole and end-systole, and, depending on the type of fibre, this change 
is local shortening, thickening, or lengthening. Finally, the average value of the strain of all 
segments is obtained [10]. From all these measurements the global longitudinal strain (GLS) 
is calculated, which is the best measure of global LV systolic function and provides relevant 
evidence on the diagnostic and prognostic implications [5, 11, 12]. 
There are many clinical scenarios in which subtle LV systolic dysfunction is present despite 
normal EF and can be characterised with GLS [6, 7, 13]. 
It seems that the use of new techniques to assess systolic function in acromegalic patients may 
shed new light on the controversial diagnosis of acromegalic cardiomyopathy. 
The aim of this study was to determine if patients with naive acromegaly, with preserved 
LVEF, present abnormal GLS in comparison with a matched control group. 
 
Material and methods 
Study population 
A total of 140 consecutive patients diagnosed with acromegaly at the Department of 
Endocrinology of the Centre of Postgraduate Medical Education, Warsaw, Poland, from 2008 
to 2016, underwent echocardiography at the Cardiology Clinic of Physiotherapy Division of 
the Second Faculty of Medicine of the Medical University of Warsaw as a routine diagnostic 
procedure. The patients were at various stages of the disease. Out of this group, we included 
43 adult patients with naive acromegaly and complete echocardiography examination, 
including GLS, for the final statistical analysis. Patients with a history of myocardial 
infarction or heart failure and impairment of LV systolic function (EF < 54% in women and < 
52% in men) were excluded from the study. Patients diagnosed with adrenal insufficiency 
and/or secondary hypothyroidism first received proper replacement with hydrocortisone 
and/or L-thyroxine. 
Acromegaly was diagnosed on the basis of the following: 
— typical acromegalic features. In most cases, old photos of the patient (5-20 years 
before) were used to estimate the onset of the disease [1,3]; 
— lack of GH suppression (< 1.0 µg/L) in the oral 75 g glucose tolerance test; 
 — elevated IGF-1 level in comparison to the normal values for age and sex; 
— pituitary adenoma in magnetic resonance imaging.  
Arterial hypertension and glucose metabolism disorders (diabetes, prediabetes) were 
diagnosed according to the guidelines of the Polish Arterial Hypertension Society [14] and 
Polish Diabetic Society [15]. 
Body mass index (BMI) was calculated as body mass in kilograms divided by height in 
metres squared (kg/m2). Values for body surface area (BSA) were recorded from the 
echocardiographic examination software. 
The control group consisted of 52 volunteers, of both sexes, recruited from the hospital 
(nurses, doctors, staff employed in administration). Initial inclusion criteria were established 
to match controls and patients for age, sex, BMI, and prevalence of hypertension and diabetes. 
Due to the relatively low number of volunteers, matching for comorbidities was impossible. 
The final inclusion criteria were age between 20 and 80 years and BMI between 20 and 40 
kg/m2. 
 
Hormone assays 
GH was tested using the immunochemiluminescence method with an Immulite 2000 analyser 
(Siemens, Los Angeles, California, USA) or Liaison XL (Dia Sorin, Italy) analyser. 
IGF-1 was tested using the immunochemiluminescence method with an Immulite 2000 
analyser (Siemens, Los Angeles, California, USA) or Liaison XL analyser (Dia Sorin, Italy). 
All plasma samples were collected in the early morning after a 12-hour fasting period. 
 
Echocardiographic examination 
Echocardiography was performed using a Vivid 4 device (Haifa, Israel) before 2012 and 
Vivid 9 device (Horten, Norway) from 2012 onwards. A sector transducer with a frequency of 
3.2 MHz was used. The images were stored digitally for later offline analysis using dedicated 
software (EchoPac PC, workstation version 113, GE Medical Systems). 
 
Strain analysis by STE 
Global longitudinal strain is the most commonly used strain-based measure of LV global 
systolic function [5, 10]. It is usually assessed by 2D-STE. GLS describes the relative length 
change of the LV myocardium between end-diastole and end-systole:  
GLS (%) = (MLs – MLd)/MLd  100, 
where ML is myocardial length at end-systole (MLs) and end-diastole (MLd). Because MLs 
 is smaller than MLd, peak GLS is a negative number [10]. 
We used the automated function imaging (AFI) application to evaluate GLS. Automated 
function imaging is clinically applicable and an effective means of assessing LV function due 
to its short acquisition time, feasibility, accuracy, and repeatability [16]. 
The analysis involved ECG-gated digital images in four-, three-, and two-chamber apical 
views, and a high temporal resolution of 50–60 frames per second was obtained to assure 
acoustic-marker tracking. Aortic valve closure was used for timing of end-systole — it was 
measured conventionally using pulsed-wave Doppler in the apical five-chamber view, and 
clicks of opening and closing the aortic valve were marked. 
If the quality of myocardial tracking was poor, the process was repeated. Only the images 
with appropriate tracking in all the myocardial segments were used in the analysis. 
Global longitudinal strain was the average of the value that was obtained for three apical 
views. 
In our study, the coefficient of variation (CV) of GLS was 1.6%. 
In accordance with the guidelines, a value of GLS of –20% or lower (i.e. more negative) was 
taken as normal in our study [10]. 
 
Standard echocardiography analyses 
The following data were recorded: 
— left ventricular diastolic dimension and myocardial thickness: interventricular septum 
(IVS), posterior wall (PW), and left ventricular mass (LVM). Measurements were 
conducted in 2D imaging. The LVM was calculated using the formula of the 
American Society of Echocardiography modified by Devereux [17]: LVM was 
indexed in accordance with BSA to obtain the left ventricular mass index (LVMI) 
value. Left ventricular hypertrophy was defined as an LVMI of > 115 g/m² in men and 
> 95 g/m² in women; 
—  diastolic function parameters [18]: 
a) E’med. (cm/s) — early diastolic velocity of the septal mitral annulus assessed with 
tissue Doppler exam, 
b) E/E' — mitral E-wave velocity divided by mitral annular velocity, 
c) E/A — mitral E-wave velocity divided by mitral A-wave velocity, 
— left atrial volume index (LAVI), measured using standard four-chamber projection and 
the curvature of the diastolic surface area of the left atrium. The value was calculated 
by EchoPac software, 
 — systolic function parameters: 
a) EF — ejection fraction was calculated according to the Simpson formula [10]. 
In case of imaging difficulties, the visual estimation method was used, as described in the 
literature [19]. Ejection fraction was assessed by two independent specialists in 
echocardiography. 
In accordance with the guidelines for the lower limit of the norm, the value of EF was 54% in 
women and 52% in men [10]. Because the EF values have no practical application when they 
are within normal limits and many variables affect this parameter (including hydration and 
heart rate), in both groups, the EF value was not recorded unless the value fell below 54% in 
women and below 52% in men. 
  
Ethics statement 
The Bioethics Committee of the Medical University of Warsaw approved the retrospective 
analysis of data obtained from echocardiograms of patients with acromegaly and testing of the 
healthy individuals representing the control group.  
 
Statistical analysis 
Normal distribution was confirmed with the Shapiro-Wilk test before data were analysed. 
Depending on the distribution of variables, appropriate tests were used for further analysis. 
Student’s t-test was used for comparison of average values of two variables with a normal 
distribution (for paired data or depending on the situation). We used nonparametric analysis 
when the null hypothesis of normal variable distribution was rejected. The medians were 
compared with the Mann-Whitney U-test. Spearman’s rho correlation coefficient (R) was 
used for continuous variables. The χ2 test was used for comparison of the basic clinical 
characteristics between the groups. Multivariate logistic regression analysis was used to 
determine which variables were predictors of GLS in patients with acromegaly. The within-
subject CV was calculated to assess GLS repeatability. The CV of selected group data was 
computed as the standard deviation divided by the mean and multiplied by 100. 
Statistical analyses were performed with a significance level of 5% (p < 0.05). The statistical 
analysis was carried out with STATISTICA 12.5 software (StatSoft Inc., Tulsa, OK, USA). 
 
 
 
 
 Results 
Comparison of patients with naive acromegaly and the control group 
There were no significant differences in sex distribution, age, or BMI between patients and 
the control group. There were significantly more patients with hypertension and diabetes in 
the acromegaly group than in the control group. A detailed comparison between patients and 
the control group in the selected variables is presented in Table 1. Echocardiographic findings 
are presented in Table 2. All measured parameters were significantly different between 
patients with naive acromegaly and the control group. The median LVMI differed 
significantly between groups. In the group of patients, there was a statistically significant 
negative correlation between LVMI and GLS (R = –0.47, p < 0.01) (Fig. 1). 
Multivariate logistic regression analysis revealed that, of the selected variables, there were no 
significant independent predictive factors for abnormal GLS value (Tab. 3). 
 
Comparison between patients with normal and abnormal GLS values 
The majority of acromegalic patients (n = 26; 60.5%) had abnormal GLS values. Patients with 
impairment in GLS had a significantly longer median duration of acromegaly symptoms 
compared to those with normal GLS values (p < 0.05). Patients with acromegaly and 
abnormal GLS had higher IGF-1 concentrations compared to those with normal GLS, 
although this parameter did not reach statistical significance. Acromegalics with abnormal 
GLS presented significantly higher values in one parameter of LV thickness, i.e. PW (p < 
0.05). We did not find a difference in the prevalence of hypertension or glucose metabolism 
abnormalities in patients with normal vs. abnormal GLS. Detailed data are presented in Table 
4. An example of GLS impairment (-16.2%) in acromegaly patients is shown in Figure 2. 
 
Discussion 
Patients with newly diagnosed acromegaly presented abnormal GLS values, which allows us 
to draw conclusions about the occurrence of subclinical systolic dysfunction in this group. 
Only a few studies assessing deformation in patients with acromegaly have been published. 
Volschan et al. assessed GLS in 37 patients with active acromegaly and obtained normal 
values. Interestingly, these values were higher than in the control group. However, it should 
be noted that the examined group was heterogeneous, and most of the patients had already 
undergone surgery and were on somatostatin analogue treatment [9]. In our previous study, in 
which we performed echocardiography in 140 patients with acromegaly at different stages of 
 treatment and disease activity, higher GLS values were obtained than in the group of 
untreated patients (GLS, in %, –19.2 vs. –17.1) [20]. These findings may suggest a beneficial 
effect of treatment on the obtained GLS values. To eliminate the potential impact of the 
applied treatment on the results, we studied a homogeneous group of patients with 
acromegaly before treatment. To the best of our knowledge, this is the first study that has 
evaluated GLS with the speckle-tracking technique in a group of naive acromegalic patients.  
The results of our study demonstrate that naive acromegaly patients had larger LVMI than the 
control subjects, and there was a negative correlation between LVMI and GLS. 
To date, many studies have assessed GLS in diseases accompanied by left ventricle 
hypertrophy, such as hypertension, diabetes mellitus, and Cushing’s disease [7, 21, 22]. 
The impact of traditional cardiovascular disease risk factors, such as arterial hypertension, 
diabetes mellitus, lipid disorders, and insulin resistance, on the microvascular system is well 
established [23]. It involves endothelial and smooth muscle cell dysfunction and vascular 
remodelling [23–26]. 
Because of this pathophysiology, abnormal GLS in this group of diseases is expected. It is 
interesting that hypertension and diabetes mellitus, which are significantly more common in 
the presence of acromegaly, were not significantly associated with GLS value in our study 
group. Similarly, other parameters, such as age, sex, BMI, and GH and IGF-1 concentrations, 
were not significantly different between the group with normal GLS results and the group 
with abnormal GLS values. IGF-1 was the most influential factor among these, but it did not 
reach statistical significance.  
The activity of the IGF-1/2 system on endothelial cells is multidirectional, both protective and 
pathological, in a range of diseases. Hence, there are objective difficulties in interpreting the 
effects of elevated IGF-1 in acromegalic patients. Both of these proteins play important roles 
in maintaining homeostasis by endothelial cells [27–29]. Insulin-like growth factor-1 
regulates vascular tone by decreasing the response to vasoconstrictor hormones, such as 
angiotensin II, norepinephrine and vasopressin, and through vascular production of the 
vasodilator nitric oxide (NO) [30]. 
Some studies suggest that IGF-1 promotes vascular smooth muscle cell proliferation and 
migration and that its expression is increased in atherosclerotic plaques, and in this sense, it is 
proatherogenic [27, 31]. On the other hand, IGF-1 is also protective both by enhancing 
endothelial cell function and by promoting plaque stability through increased vascular smooth 
muscle cell survival [27, 28]. 
Low IGF-1 levels result in insulin resistance and accelerated atherosclerosis and consequently 
 correlate with an increased risk of adverse cardiovascular outcomes, including myocardial 
infarction and heart failure [27, 32]. Additionally, IGF-1 affects the number and function of 
endothelial progenitor cells, which decrease with age. These adverse changes can be reversed 
by increasing IGF-1 levels with GH treatment [27, 33]. 
In a study by Tellatin et al. the relationship of coronary microvascular impairment with 
elevated levels of IGF-1 in acromegalic patients was assessed [34]. Forty patients (28 with 
active acromegaly) were included in the study, and all had non-invasive coronary flow reserve 
(CFR) assessment using transthoracic doppler echocardiography. Thirteen patients had 
abnormal results (CFR < 2.5), which independently correlated with IGF-1 level. In addition, 
CFR was improved during treatment in some patients. 
Anagnostis et al. also showed an adverse effect of active acromegaly on endothelial function 
[35]. They evaluated total antioxidant capacity measured by catalase activity and glutathione 
concentration, oxidative stress measured by oxidised glutathione and thiobarbituric acid-
reactive substances, and NO levels. They found increased oxidative stress, decreased 
antioxidative capacity, and reduced NO levels in acromegalic patients compared to controls. 
Our findings are similar and show that patients with active untreated acromegaly with normal 
EF have subclinical systolic dysfunction as assessed by decreased GLS, which is probably 
due to the negative effect of IGF-1 on the microvascular system.  
In our group of patients with normal GLS (39.5%), the mean IGF-1 value was only nominally 
lower than in the group with abnormal GLS (741.9 ± 245.1 vs. 932.3 ± 350.8); the difference 
was not statistically significant, although this value was clearly above the norm for the 
patients’ age and sex. The occurrence of hypertension and diabetes did not differ significantly 
between the groups. It can be argued that the reason we obtained good GLS results is that the 
positive effect of IGF-1 predominates over its pathological effect on the microvascular 
system. 
However, there is an open and interesting question about why other patients with high IGF-1 
values have abnormal GLS. Perhaps there is an IGF-1 value above which its detrimental 
effect on endothelial cells dominates. Maybe patients treated with somatostatin analogues do 
not have to reach the norm for age and sex, and maybe the group of patients with no 
improvement in GLS values should be treated for prevention of overt cardiac failure. This is 
an interesting issue for further studies. 
 
Study limitations 
The study was limited by the fact that until 2012, examinations were performed using the 
 Vivid 4 echocardiograph, which had lower technical capabilities than the Vivid 9 device. The 
Vivid 9 device was used for the majority of patients and all controls. Because GLS is partially 
dependent on the echocardiograph and the applied software as well as the researcher's 
experience, comparing the results obtained in our study with the results of other studies can be 
a limitation. Data regarding the duration of symptoms were self-reported by patients, which 
means the data are not accurate and constitute a limitation of this study. Another study 
limitation was the low number of patients. 
 
Conclusions 
Naive acromegalic patients presented with lower GLS compared to the control group, 
revealing subclinical systolic dysfunction in patients with naive, untreated acromegaly.  
It has not been proven that arterial hypertension and diabetes mellitus, which are significantly 
more common in acromegaly, are significant determinants of abnormal GLS.  
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Table 1. Characteristics of patients and the control group regarding the occurrence of co-
morbidities and biochemical parameters 
 
 Patients with acromegaly  
(n = 43) 
Control group  
(n = 52) 
p value 
Age [years] 48.2 ± 14.2 47.4 ± 12.3 0.76 
Sex (♀/♂, n) 25/18 27/25 0.55 
BMI [kg/m2] 29.8 ± 5.0 27.9 ± 4.6 0.06 
BSA [m2] 2.01 ± 0.23 1.97 ± 0.22 0.33 
Duration of acromegaly 
symptoms [years] 
10.0 (2.0–40.0) N/A – 
GH levels [μg/L] 8.5 (1.0–79.0) N/A – 
IGF-1 level [μg/L] 783.6 (321.0–1600.0) N/A – 
Hypertension (Yes/No) 26/17 17/35 < 0.01 
Diabetes status 
(Diabetes/Prediabetes/
No)  
8/23/12 0/3/49 < 0.001 
BMI — body mass index; BSA — body surface area; GH — growth hormone; IGF-1 —
insulin-like growth factor-1; N/A — not applicable 
 
Table 2. Echocardiography parameters in patients with acromegaly versus control group 
 Patients with 
acromegaly (n = 43) 
Control group  
(n = 52) 
p value 
Cardiac chamber size    
LVEDd [mm] 49.0 (24.0–63.0) 47.0 (39.0–58.0) < 0.05 
LAVI [mL/m2] 43.0 (27.3–97.3) 29.9 (15.9–53.3) < 0.001 
LV mass    
IVS [mm] 12.0 (8.0–19.0) 10.0 (7.0–15.0) < 0.001 
PW [mm] 12.0 (8.0–17.0) 10.0 (7.0–14.0) < 0.001 
LVMi [g/m2] 136.0 (77.0–236.0) 97.0 (44.0–163.0) < 0.001 
Diastolic function    
E’med. [cm/s] 7.0 (4.0–12.0) 9.0 (5.0–18.0) < 0.001 
 E/E’ 9.0 (5.0–24.0) 8.0 (5.0–13.0) < 0.05 
E/A 0.9 (0.5–1.8) 1.2 (0.5–2.3) < 0.05 
Systolic function    
GLS (%) –16.6 (–8.4– –26.5) –20.7 (–14.6– –30.2) < 0.001 
LVEDd — left ventricular end diastolic diameter; LAVI — left atrial volume index; LV — 
left ventricular; IVS — interventricular septum; PW — posterior wall; LVMi — left 
ventricular mass index; E’med. — early diastolic velocity of the septal mitral annulus; E/E' — 
mitral E-wave velocity divided by mitral annular velocity; E/A — mitral E-wave velocity 
divided by mitral A-wave velocity; GLS — global longitudinal strain 
 
Table 3. Multivariate logistic regression analysis for global longitudinal strain (GLS)  
Dependent 
variable 
Predictors Odds ratio 95% CI p value 
GLS 
Age 0.97 0.90–1.05 0.43 
Sex 0.85 0.21–3.49 0.82 
GH 0.98 0.94–1.03 0.48 
IGF-1 1.00 0.99–1.01 0.15 
Hypertension  0.56 0.09–3.59 0.54 
Diabetes 1.72 0.32–9.41 0.97 
GLS — global longitudinal strain (1 — abnormal value, 0 — value of normal range); GH — 
growth hormone; IGF-1 — insulin-like growth factor 1; CI — confidence interval  
 
Table 4. Characteristics of acromegalic patients with normal and abnormal global 
longitudinal strain (GLS) 
 Patients with 
acromegaly with 
normal GLS 
Patients with 
acromegaly with 
abnormal GLS 
p value 
Age [years] 51.5 ± 14.1 46.0 ± 14.1 0.22 
Sex (♀/♂) 11/6 14/12 0.48 
BMI [kg/m2] 29.6 ± 4.3 29.9 ± 5.5 0.87 
BSA [m2] 2.01 ± 0.22 2.02 ± 0.24 0.88 
Duration of acromegaly 
symptoms [years] 
5.0 (2.0–40.0) 10.0 (3.0–40.0) < 0.05 
 GH [μg/L] 5.7 (1.0–79.2) 11.2 (2.2–70.1) 0.18 
IGF-1 [μg/L] 673.0 (408.0–1162.0) 813.0 (321.1–1600.0) 0.07 
Hypertension (Yes/No) 10/7 16/10 0.86 
Diabetes status 
(Diabetes/Prediabetes/
No)  
3/10/4 5/13/8 0.84 
Cardiac chamber size    
LVEDd [mm] 49.0 (24.0–63.0) 49.0 (40.0–57.0) 0.78 
LAVI [mL/m2] 39.9 (27.3–61.9) 46.2 (29.6–97.3) 0.13 
LV mass    
IVS [mm] 12.0 (8.0–14.0) 12.5 (8.0–19.0) 0.08 
PW [mm] 12.0 (9.0–13.0) 12.5 (8.0–17.0) < 0.05 
LVMI [g/m2] 126.0 (77.0–180.0) 141.5 (79.0–236.0) 0.08 
Diastolic function    
E'med. [cm/s] 8.0 (4.0–11.0) 6.5 (4.0–12.0) 0.54 
E/E' 9.0 (6.0–15.0) 9.0 (5.0–24.0) 0.95 
E/A 0.9 (0.6–1.5) 0.9 (0.5–1.8) 0.99 
BMI — body mass index; BSA — body surface area; GH — growth hormone; IGF-1 —
insulin-like growth factor-1; LVEDd — left ventricular end diastolic diameter; LAVI — left 
atrial volume index; LV — left ventricular; IVS — interventricular septum; PW — posterior 
wall; LVMi — left ventricular mass index; E’med. — early diastolic velocity of the septal 
mitral annulus; E/E' — mitral E-wave velocity divided by mitral annular velocity; E/A — 
mitral E-wave velocity divided by mitral A-wave velocity; GLS — global longitudinal strain 
 
Figure 1. Correlation between left ventricular mass index (LVMI) and global longitudinal 
strain (GLS) in acromegaly group 
  
 
Figure 2. Global longitudinal strain (GLS) impairment in patients with naive acromegaly 
 
 
